Affinage

JMJD1C

Jumonji domain-containing protein 1C · UniProt Q15652

Length
2540 aa
Mass
284.5 kDa
Annotated
2026-04-28
52 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JMJD1C is a JmjC domain-containing lysine demethylase that removes mono- and di-methyl marks from histone H3K9 at specific gene promoters to activate transcription, functioning as a chromatin-based coactivator across diverse biological contexts including leukemia stem cell self-renewal, spermatogenesis, lipogenesis, adipogenesis, embryonic stem cell maintenance, and immune cell differentiation (PMID:20530532, PMID:26494788, PMID:26878175, PMID:32034158, PMID:24006281, PMID:28826851). Beyond histone substrates, JMJD1C demethylates the non-histone proteins MDC1 at Lys45—enabling RNF8-dependent ubiquitylation and BRCA1 recruitment during the DNA damage response—and STAT3 at Lys140, which promotes PTPN6 phosphatase engagement to restrain STAT3 phosphorylation and plasma cell differentiation (PMID:24240613, PMID:35995859). JMJD1C activity is regulated post-translationally by mTOR-mediated phosphorylation at Thr505, which licenses interaction with the transcription factor USF-1 at lipogenic promoters, and by Deltex2-induced monoubiquitination, which inhibits its catalytic demethylase function (PMID:32034158, PMID:28351977). In leukemia, JMJD1C is recruited by RUNX1-RUNX1T1 and HOXA9 to sustain oncogenic gene expression programs, and its catalytic JmjC and zinc finger domains are essential for MLL-rearranged AML cell survival (PMID:26494788, PMID:26878175, PMID:31076406).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2007 Medium

    The first functional characterization established that a splice variant of JMJD1C directly binds the androgen receptor and acts as a nuclear receptor coactivator, positioning it as a transcriptional regulator.

    Evidence Yeast two-hybrid, GST pull-down, and mammalian one-hybrid in cell lines

    PMID:17353003

    Open questions at the time
    • No demethylase activity was demonstrated in this study
    • Chromatin occupancy at AR target genes not tested
    • Physiological relevance of the AR interaction in vivo not addressed
  2. 2010 High

    Defining JMJD1C as a bona fide H3K9me1/me2 demethylase resolved its catalytic identity and revealed its sequential promoter switch with the methyltransferase WHISTLE at steroidogenic genes.

    Evidence In vitro demethylation assay, TAP purification identifying WHISTLE and HSP90α, ChIP at p450c17 promoter in mouse testis

    PMID:20530532

    Open questions at the time
    • Genome-wide target repertoire of JMJD1C not mapped
    • Whether HSP90α binding modulates catalytic activity was not tested
  3. 2013 High

    Discovery that JMJD1C demethylates the non-histone substrate MDC1 at Lys45 established a new paradigm in which its catalytic activity directly regulates the RNF8–BRCA1 DNA damage response pathway, broadening its function beyond chromatin.

    Evidence In vitro demethylation assay on MDC1, Co-IP of JMJD1C–RNF8–MDC1, laser-stripe DSB recruitment, site-specific mutagenesis

    PMID:24240613

    Open questions at the time
    • Whether JMJD1C demethylates MDC1 at DSBs in a cell-cycle-dependent manner was not addressed
    • In vivo physiological consequences of losing this DDR function not tested
  4. 2013 Medium

    Demonstration that JMJD1C maintains undifferentiated spermatogonia and sustains miR-302 expression in human ESCs revealed its role in stem cell self-renewal through H3K9 demethylation at specific regulatory loci.

    Evidence Jmjd1c KO mouse testis phenotyping; shRNA knockdown in hESCs with ChIP at miR-302 promoter

    PMID:24006281 PMID:24318875

    Open questions at the time
    • Genome-wide H3K9me2 changes in spermatogonia not characterized
    • Whether demethylase activity is required for the spermatogonial phenotype was not directly tested
  5. 2015 High

    Identification of JMJD1C as a critical coactivator recruited by RUNX1-RUNX1T1 in AML—maintaining low H3K9me2 at leukemic target loci—established its oncogenic role and therapeutic relevance in leukemia.

    Evidence ChIP-seq, Co-IP, Jmjd1c KO mouse with RUNX1-RUNX1T1-driven proliferation assay

    PMID:26494788

    Open questions at the time
    • Whether H3K9 demethylase activity alone or a scaffolding function is responsible was not dissected
    • No structural basis for RUNX1-RUNX1T1 interaction determined
  6. 2015 Medium

    A Rett syndrome-associated JMJD1C mutation was shown to impair its demethylase activity and MECP2 binding, providing initial evidence linking JMJD1C dysfunction to a neurodevelopmental disorder.

    Evidence Functional mutagenesis, in vitro MDC1 demethylation assay, Co-IP of JMJD1C–MECP2, neuronal knockdown

    PMID:26181491

    Open questions at the time
    • Single patient mutation; causal relationship to Rett syndrome not genetically established
    • Neuronal H3K9me2 target loci not identified
    • Whether MECP2 binding is direct or bridged was not resolved
  7. 2016 High

    Establishing JMJD1C as a direct HOXA9 partner required for leukemia stem cell self-renewal in MLL-rearranged AML clarified its oncogenic mechanism and showed therapeutic selectivity over normal HSCs.

    Evidence In vivo shRNA screen, conditional KO, Co-IP of JMJD1C–HOXA9, serial transplantation

    PMID:26878175

    Open questions at the time
    • The specific gene targets co-regulated by JMJD1C and HOXA9 were not fully delineated
    • Catalytic versus scaffolding contribution not separated
  8. 2017 High

    Discovery that Deltex2 inhibits JMJD1C by promoting its monoubiquitination revealed the first post-translational mechanism controlling JMJD1C catalytic activity, with functional consequences for MyoD expression and myogenesis.

    Evidence Co-IP, in vitro demethylase assay, monoubiquitination-site mutagenesis, ChIP at MyoD locus, muscle stem cell rescue experiments

    PMID:28351977

    Open questions at the time
    • The E3 ligase catalyzing monoubiquitination was not identified
    • Whether monoubiquitination regulates JMJD1C in non-muscle contexts was not tested
  9. 2017 Medium

    Work in mESCs and preadipocytes extended the H3K9 demethylation paradigm to pluripotency (miR-200/miR-290 family loci via KLF4) and adipogenesis (C/EBP and PPARγ promoters), broadening the physiological scope of JMJD1C function.

    Evidence shRNA in mESCs with ChIP and MEK inhibitor rescue; shRNA in 3T3-L1 with ChIP at adipogenic promoters

    PMID:28501567 PMID:28826851

    Open questions at the time
    • Whether KLF4 directly recruits JMJD1C was not tested biochemically
    • In vivo adipogenesis phenotype not confirmed in KO mice
  10. 2019 Medium

    Domain-resolution CRISPR screening in MLL-rearranged AML showed that both the JmjC catalytic domain and zinc finger domain are essential for leukemia survival, and identified H3K36 methylation as a potential JMJD1C activity mark, expanding its substrate range beyond H3K9.

    Evidence CRISPR/Cas9 domain-specific negative-selection screen, ChIP for H3K36me, single-cell transcriptomics, RAS epistasis

    PMID:31076406

    Open questions at the time
    • Direct H3K36 demethylation by JMJD1C not demonstrated in vitro in this study
    • Whether H3K36 and H3K9 demethylation are context-dependent was not resolved
  11. 2020 High

    Identification of mTOR-mediated Thr505 phosphorylation as a nutrient-responsive switch enabling JMJD1C–USF-1 interaction at lipogenic promoters established a signaling-to-chromatin mechanism for feeding-induced lipogenesis.

    Evidence In vivo phosphorylation mapping, T505A mutagenesis, Co-IP with USF-1, ChIP at FASN/GPAT, hepatic triglyceride measurements in mice

    PMID:32034158

    Open questions at the time
    • Whether additional kinases regulate JMJD1C was not explored
    • Structural basis of USF-1 recognition of phospho-T505 not determined
  12. 2022 High

    Demonstration that JMJD1C demethylates STAT3 at Lys140 to enable PTPN6 phosphatase docking established a second non-histone demethylation event with direct signaling consequences, explaining how JMJD1C restrains plasma cell differentiation.

    Evidence B cell-specific Jmjd1c KO, in vitro STAT3 demethylation assay, K140R mutagenesis, Co-IP of STAT3–PTPN6, flow cytometry

    PMID:35995859

    Open questions at the time
    • Whether JMJD1C demethylates STAT3 in non-B cell contexts was not tested
    • Full set of non-histone substrates remains unknown
  13. 2024 Medium

    Treg-specific deletion revealed a dual mechanism in tumor immunity: JMJD1C loss enhances AKT signaling via H3K9me2 demethylase activity and boosts STAT3 signaling through a demethylase-independent mechanism, inducing Treg fragility and anti-tumor immunity.

    Evidence Treg-specific Jmjd1c KO, ChIP for H3K9me2, STAT3 pathway dissection, oral JMJD1C inhibitor in tumor models

    PMID:38356061

    Open questions at the time
    • The demethylase-independent mechanism of STAT3 regulation in Tregs is undefined
    • Selectivity and pharmacology of the oral JMJD1C inhibitor not deeply characterized

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the complete catalog of JMJD1C non-histone substrates, the structural basis for its interactions with transcription factors and regulation by post-translational modifications, and whether its H3K36 demethylase activity is physiologically significant.
  • No crystal or cryo-EM structure of JMJD1C or its complexes exists
  • Full non-histone substrate repertoire uncharacterized
  • H3K36 demethylation not validated by direct in vitro assay
  • Relative contributions of catalytic versus scaffolding functions unresolved in most contexts

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0042393 histone binding 5 GO:0140110 transcription regulator activity 4
Localization
GO:0005634 nucleus 5 GO:0005694 chromosome 3
Pathway
R-HSA-4839726 Chromatin organization 7 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 2 R-HSA-73894 DNA Repair 1
Partners
DTX2HOXA9HSP90AA1MDC1RNF8RUNX1STAT3USF1

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 JMJD1C is a histone/protein demethylase that demethylates MDC1 at Lys45, promoting MDC1-RNF8 interaction, RNF8-dependent MDC1 ubiquitylation, and recruitment of the RAP80-BRCA1 complex to DNA double-strand breaks. JMJD1C binds both RNF8 and MDC1 directly, is stabilized by RNF8 interaction, and is recruited to DSBs where it specifically regulates the BRCA1 branch (but not 53BP1 branch) of the DNA damage response. Co-immunoprecipitation, in vitro demethylation assay, site-specific mutagenesis, laser-induced DSB recruitment imaging, RNAi knockdown with defined epistasis Nature structural & molecular biology High 24240613
2010 JMJD1C specifically demethylates histone H3K9 mono- and di-methylation and mediates transcriptional activation. It forms a complex with WHISTLE (a histone methyltransferase) and HSP90α. In mouse testis, JMJD1C and WHISTLE sequentially occupy the p450c17 promoter via SF-1: WHISTLE represses transcription prepubertally, then JMJD1C replaces it to activate steroidogenesis target genes. Immunoaffinity TAP purification, in vitro H3K9 demethylation assay, ChIP, co-immunoprecipitation, gene expression analysis Nucleic acids research High 20530532
2015 JMJD1C functions as a transcriptional coactivator for RUNX1-RUNX1T1 (AML1-ETO) in AML. It is directly recruited by RUNX1-RUNX1T1 to target gene loci and maintains low H3K9me2 levels at these loci to sustain their expression. Loss of JMJD1C in knockout mice impairs RUNX1-RUNX1T1-driven proliferation. ChIP-seq, co-immunoprecipitation, JMJD1C knockout mouse model, shRNA knockdown, gene expression profiling Genes & development High 26494788
2016 JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program required for MLL-AF9 and HOXA9-driven leukemia stem cell (LSC) self-renewal. Loss of JMJD1C substantially decreases LSC frequency and causes differentiation of these leukemias, while having only minor effects on normal hematopoietic stem cells. In vivo shRNA screen, conditional mouse knockout, co-immunoprecipitation (JMJD1C–HOXA9), transplantation assays The Journal of clinical investigation High 26878175
2020 JMJD1C is phosphorylated at Thr505 by mTOR complex in response to feeding/insulin, enabling its direct interaction with USF-1 and recruitment to lipogenic gene promoters (e.g., FASN, GPAT). At these promoters, JMJD1C demethylates H3K9me2 to increase chromatin accessibility and activate transcription of lipogenic genes, thereby promoting hepatic and plasma triglyceride synthesis. In vivo phosphorylation mapping, co-immunoprecipitation (JMJD1C–USF-1), ChIP, shRNA knockdown in mouse liver, in vivo lipid measurements, site-directed mutagenesis (T505A) Nature communications High 32034158
2022 JMJD1C demethylates STAT3 at Lys140 (a non-histone substrate) in B cells, which promotes STAT3 interaction with phosphatase PTPN6 and restricts sustained STAT3 phosphorylation. Loss of JMJD1C causes STAT3 Lys140 hypermethylation, blocking PTPN6 binding, sustaining STAT3 phosphorylation, and driving plasma cell differentiation. STAT3 K140R point mutation completely abrogates the effect of JMJD1C deletion. B cell-specific Jmjd1c knockout, in vitro demethylation assay on STAT3, co-immunoprecipitation (STAT3–PTPN6), site-directed mutagenesis (K140R), flow cytometry of plasma cells Nature immunology High 35995859
2007 A splice variant of JMJD1C (s-JMJD1C) binds directly to the androgen receptor (AR) via its ligand-binding domain. s-JMJD1C is a nuclear-localized protein that functions as an AR coactivator, identified by yeast two-hybrid and validated by GST pull-down and mammalian one-hybrid assays. Yeast two-hybrid screen, GST pull-down, mammalian one-hybrid assay, RACE for splice variant characterization Archives of biochemistry and biophysics Medium 17353003
2013 JMJD1C, as an H3K9 demethylase, binds the miR-302 promoter in human embryonic stem cells (hESCs) and reduces H3K9 methylation there to sustain miR-302 expression, thereby repressing neural differentiation. JMJD1C knockdown reduces BMP signaling, enhances TGFβ signaling, and elevates NR2F2, collectively promoting neural differentiation upon bFGF withdrawal. Stable shRNA knockdown in hESCs, ChIP for H3K9 methylation at miR-302 promoter, BMP/TGFβ signaling assays, differentiation assays The Journal of biological chemistry Medium 24318875
2017 Deltex2 directly inhibits Jmjd1c demethylase activity by promoting its monoubiquitination; mutation of the monoubiquitination site in Jmjd1c abolishes Deltex2's inhibitory effect. Jmjd1c is required for MyoD expression in vivo and in vitro by demethylating H3K9me2 at a key regulatory region of the MyoD locus, thereby promoting myogenic differentiation. Co-immunoprecipitation (Deltex2–Jmjd1c), in vitro demethylase activity assay, site-directed monoubiquitination mutagenesis, ChIP for H3K9me2, genetic rescue experiments in skeletal muscle stem cells Proceedings of the National Academy of Sciences of the United States of America High 28351977
2017 JMJD1C, with the help of pluripotency factor KLF4, maintains mouse ESC identity by demethylating H3K9 at promoters of the miR-200 family and miR-290/295 cluster, suppressing ERK/MAPK signaling and EMT. Jmjd1c depletion activates ERK/MAPK signaling, and ERK/MAPK inhibition rescues the differentiation phenotype. shRNA knockdown in mESCs, ChIP for H3K9 methylation, ERK/MAPK signaling assays, epistasis with MEK inhibitor, microRNA expression profiling Stem cell reports Medium 28826851
2015 A JMJD1C mutation found in a Rett syndrome patient causes abnormal subcellular localization of JMJD1C, diminished demethylase activity toward MDC1, and reduced binding to MECP2. JMJD1C depletion in neurons compromises dendritic activity. Functional mutagenesis study, in vitro MDC1 demethylation assay, co-immunoprecipitation (JMJD1C–MECP2), subcellular localization imaging, neuronal knockdown Genetics in medicine Medium 26181491
2019 The catalytic JmjC domain and zinc finger domain of JMJD1C are required for leukemia cell survival in vitro and in vivo in MLL-rearranged AML. H3K36 methylation serves as a marker for JMJD1C activity at gene loci. Loss of JmjC domain activity leads to increased RAS/MAPK and JAK-STAT pathway activation and upregulation of IL-3 receptor genes, with activating RAS mutations conferring resistance to JMJD1C loss. CRISPR/Cas9 domain-specific negative-selection screen, single-cell transcriptomics, ChIP for H3K36me, transplantation assays, genetic epistasis with RAS mutations Blood advances Medium 31076406
2013 JMJD1C is required for long-term maintenance of undifferentiated spermatogonia (ZBTB16-positive) in mouse testis. Jmjd1c-deficient males show progressive reduction of germ cells and increased apoptosis in an age-dependent manner, with JMJD1C most abundantly expressed in undifferentiated spermatogonia. Jmjd1c knockout mouse model, immunostaining for spermatogonial markers, TUNEL apoptosis assay, histological analysis Biology of reproduction Medium 24006281
2016 JMJD1C has multiple spermatogenic functions: it is required for postmeiotic chromatin remodeling (histone H4K16 acetylation) and spermatogonial stem cell self-renewal (OCT4 expression), and it interacts with MDC1 and HSP90 as partner proteins during spermatogenesis. Gene-trap mouse model, immunostaining for H4K16ac, OCT4, and NANOG in spermatogonia, co-immunoprecipitation (JMJD1C–MDC1, JMJD1C–HSP90) PloS one Medium 27649575
2025 Jmjd1c acts as an anti-nociceptive regulator of neuropathic pain by positively regulating Socs3 expression via H3K9 demethylation at the Socs3 promoter, thereby suppressing JAK/STAT3 signaling. KLF15 activates Jmjd1c transcription by binding to its super-enhancer. H3K27ac ChIP-Seq, RNA-Seq, ChIP-qPCR for H3K9 methylation at Socs3 promoter, dual-luciferase reporter assay (KLF15–Jmjd1c SE), shRNA knockdown and overexpression in rat NP model Genes & diseases Medium 40485981
2024 In tumor Treg cells, JMJD1C deletion enhances AKT signaling through its H3K9me2 demethylase activity and increases STAT3 signaling independently of H3K9me2 demethylase activity, collectively leading to robust IFN-γ production and Treg cell fragility. An oral JMJD1C inhibitor suppresses tumor growth by targeting intratumoral Treg cells. Treg-specific Jmjd1c knockout, ChIP for H3K9me2, STAT3 pathway analysis, pharmacological inhibition, tumor growth assays Nature immunology Medium 38356061
2017 Jmjd1c depletion in 3T3-L1 preadipocytes impairs mitotic clonal expansion and increases H3K9me2 at promoters of key adipogenic transcription factors (C/EBPs and PPARγ), reducing their induction and impairing adipocyte differentiation, lipid droplet formation, and insulin-stimulated glucose/fatty acid uptake. shRNA knockdown in 3T3-L1, ChIP for H3K9me2 at C/EBP and PPARγ promoters, lipid staining, glucose/fatty acid uptake assays Biochimica et biophysica acta. Molecular basis of disease Medium 28501567
2022 JMJD1C interacts with FABP5 via its jumonji domain in MLL-rearranged AML cells, and FABP5 regulates JMJD1C mRNA and protein expression. JMJD1C regulates expression of lipid synthesis-associated genes FADS2 and SCD. Mass spectrometry interactome, co-immunoprecipitation (JMJD1C–FABP5), domain mapping, gene expression analysis, pharmacological rescue with lipids/recombinant FABP5 Leukemia & lymphoma Low 35468015
2026 Endothelial JMJD1C drives pathological ocular neovascularization by demethylating H3K9me2 at the Srebf2 locus to activate SREBF2-dependent cholesterol biosynthesis in endothelial cells. Endothelial-specific Jmjd1c deletion suppresses Srebf2 transcription, increases H3K9me2 at this locus, and markedly reduces pathological neovascularization in OIR and CNV mouse models. Endothelial-specific conditional Jmjd1c KO, ChIP-qPCR for H3K9me2 at Srebf2 locus, RNA-seq, in vitro angiogenesis assays, in vivo retinal flat-mount and CNV models Free radical biology & medicine Medium 41548765
2024 JMJD1C promotes PCSK9 transcription in macrophages through H3K9 demethylation at the PCSK9 locus, driving foam cell formation and atherosclerosis progression. JMJD1C knockdown reduces plaque area and foam cell formation, effects reversed by PCSK9 overexpression. ChIP for H3K9 demethylation at PCSK9 promoter, shRNA knockdown in RAW264.7 cells and ApoE-/- mice, PCSK9 rescue overexpression Journal of physiology and biochemistry Low 39511107
2024 In PNH clones, elevated JMJD1C demethylates H3K36me3 at the CPS1 locus (reducing H3K36me3), suppressing CPS1 expression and promoting metabolic reprogramming that sustains clonal proliferation. JMJD1C knockdown in PIG-A KO K562 cells upregulates CPS1 and H3K36me3 and decreases proliferation. ChIP analysis of H3K36me3 at CPS1 locus, shRNA knockdown in K562 PIG-A KO cells, CPS1 expression and metabolic measurements, pharmacological inhibition with JIB-04 British journal of haematology Low 38650379

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nature structural & molecular biology 85 24240613
2015 JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes & development 74 26494788
2016 MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. The Journal of clinical investigation 72 26878175
2014 shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 68 24501218
2010 Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic acids research 67 20530532
2007 Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism. European journal of human genetics : EJHG 62 17290275
2020 Histone demethylase JMJD1C is phosphorylated by mTOR to activate de novo lipogenesis. Nature communications 61 32034158
2013 JMJD1C, a JmjC domain-containing protein, is required for long-term maintenance of male germ cells in mice. Biology of reproduction 58 24006281
2007 A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Archives of biochemistry and biophysics 56 17353003
2003 Identification and characterization of TRIP8 gene in silico. International journal of molecular medicine 52 14533015
2022 Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis. Nature immunology 46 35995859
2021 Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a. Clinical and translational medicine 44 34586733
2013 Epigenetic regulation of miR-302 by JMJD1C inhibits neural differentiation of human embryonic stem cells. The Journal of biological chemistry 43 24318875
2015 Mutations in JMJD1C are involved in Rett syndrome and intellectual disability. Genetics in medicine : official journal of the American College of Medical Genetics 42 26181491
2019 JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 39 30622285
2019 Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. International journal of cancer 35 31271662
2017 Deltex2 represses MyoD expression and inhibits myogenic differentiation by acting as a negative regulator of Jmjd1c. Proceedings of the National Academy of Sciences of the United States of America 34 28351977
2024 Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity. Nature immunology 32 38356061
2021 Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis. Cancer cell international 31 34022910
2019 Histone Lys demethylase KDM3C demonstrates anti-inflammatory effects by suppressing NF-κB signaling and osteoclastogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28 31251083
2018 Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. American journal of cancer research 27 29888107
2007 Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer. International journal of oncology 27 17549425
2020 Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II. Journal of receptor and signal transduction research 25 32122211
2020 The Histone Demethylase JMJD1C Regulates CAMKK2-AMPK Signaling to Participate in Cardiac Hypertrophy. Frontiers in physiology 25 32625104
2019 Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia. Blood advances 25 31076406
2017 Histone demethylase JMJD1C regulates esophageal cancer proliferation Via YAP1 signaling. American journal of cancer research 25 28123852
2017 Depletion of Jmjd1c impairs adipogenesis in murine 3T3-L1 cells. Biochimica et biophysica acta. Molecular basis of disease 25 28501567
2023 JMJD1C promotes smooth muscle cell proliferation by activating glycolysis in pulmonary arterial hypertension. Cell death discovery 23 36934091
2017 JMJD1C Ensures Mouse Embryonic Stem Cell Self-Renewal and Somatic Cell Reprogramming through Controlling MicroRNA Expression. Stem cell reports 19 28826851
2016 Knockdown of JMJD1C, a target gene of hsa-miR-590-3p, inhibits mitochondrial dysfunction and oxidative stress in MPP+-treated MES23.5 and SH-SY5Y cells. Cellular and molecular biology (Noisy-le-Grand, France) 19 27064872
2013 A mediator methylation mystery: JMJD1C demethylates MDC1 to regulate DNA repair. Nature structural & molecular biology 15 24304913
2024 Jia Wei Qingxin Lotus Seed Drink ameliorates epithelial mesenchymal transition injury in diabetic kidney disease via inhibition of JMJD1C/SP1/ZEB1 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 14 39541663
2016 JMJD1C Exhibits Multiple Functions in Epigenetic Regulation during Spermatogenesis. PloS one 13 27649575
2022 JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia. Leukemia & lymphoma 9 35468015
2021 AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. Proceedings of the National Academy of Sciences of the United States of America 9 34475205
2020 Modulators of histone demethylase JMJD1C selectively target leukemic stem cells. FEBS open bio 9 33289299
2015 Expression pattern of JMJD1C in oocytes and its impact on early embryonic development. Genetics and molecular research : GMR 9 26782472
2024 Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications. Cell death & disease 8 38926399
2022 Histone demethylase KDM3C regulates the lncRNA GAS5-miR-495-3p-PHF8 axis in cardiac hypertrophy. Annals of the New York Academy of Sciences 8 35777757
2020 Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice. PloS one 7 32017785
2021 JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity. Pharmacogenetics and genomics 6 33075016
2020 Jumonji domain containing 1C (JMJD1C) sequence variants in seven patients with autism spectrum disorder, intellectual disability and seizures. European journal of medical genetics 6 31954878
2024 BRD4 expression and its regulatory interaction with miR-26a-3p, DLG5-AS1, and JMJD1C-AS1 lncRNAs in gastric cancer progression. Discover oncology 3 39152304
2024 Histone demethylase JMJD1C advances macrophage foam cell formation and atherosclerosis progression by promoting the transcription of PCSK9. Journal of physiology and biochemistry 3 39511107
2022 JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network. Cells 3 36429088
2024 circ_JMJD1C expedites breast cancer progression by regulating miR-182-5p/JMJD1C/SOX4 axis. Cellular and molecular biology (Noisy-le-Grand, France) 2 38650133
2024 The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of paroxysmal nocturnal haemoglobinuria clones through cell metabolic reprogramming. British journal of haematology 2 38650379
2017 Polymorphisms in JMJD1C are associated with pubertal onset in boys and reproductive function in men. Scientific reports 2 29222425
2025 Enhancer profiling uncovers Jmjd1c as an essential suppressor in neuropathic pain by targeting Socs3. Genes & diseases 1 40485981
2026 Endothelial JMJD1C drives pathological ocular neovascularization by activating SREBF2-dependent cholesterol biosynthesis. Free radical biology & medicine 0 41548765
2026 [Jia Wei Qingxin Lotus Seed Drink improves diabetic kidney disease in mice by regulating the KDM3C/SP1 signaling pathway]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 0 42045024
2025 Transcriptomic and network analyses of an alcohol-induced peripheral neuropathy model identify putative role for histone demethylase Jmjd1c. bioRxiv : the preprint server for biology 0 41279904